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Abstract
Background: Bland and Altman have published their method of differences in 1986 in the Lancet to draw their method to the attention of 
medical professionals. Bland and Altman always have pointed out that their method of differences is designed to detect bias between methods. 
Their statistical methodology has found its way among clinical chemists, but it has been criticized in 2002 that a high proportion of clinical 
chemists misinterpreted or misused the methods of differences. It seems that the Nephrology community is falling into the same traps as clinical 
chemists if they use the method of differences to compare estimating glomerular filtration rate (eGFR) equations with the direct measurement of 
GFR (mGFR).
Methods: Using simulated data and a real life example, we demonstrate how the method of differences should be used appropriately.
Findings: The main points of criticism are that proportional bias is not analysed correctly and that the calculated 95% limits of agreement 
should be compared to predefined clinically acceptable limits.
Interpretation: There is no need to introduce ‘alternative’ statistics like absolute mean difference, accuracy within 30%, etc when the Bland-
Altman methodology is correctly applied. The goal of method comparison is to demonstrate how close the new method is to the (g)old method. 
The final decision to accept or reject the eGFR-equation is a clinical decision, not a statistical decision. The real problem with currently available 
eGFR-equations is that none of these equations are close enough to the measured GFR so that the eGFR-equation can replace the measured 
GFR.
Keywords: Bland-Altman methodology; Proportional bias; Estimating glomerular filtration rate; 95% limits of agreement
Introduction
In 1986, Bland and Altman published “Statistical methods for assessing 
agreement between two methods of clinical measurement” in the Lancet 
[1], to draw their method, earlier published in the Statistician [2], to the 
attention of medical professionals. It has been cited more than 30000 
times since then. In that article, Bland and Altman described their 
method of differences for analysing method comparison studies. The 
method consists of plotting the differences between the values resulting 
from the two methods of measurement (Y) against the average of the 
values (X). The statistical analysis that should be performed on this plot 
evolved over some 16 years [3,4]. Bland and Altman always have pointed 
out that their method of differences is designed to detect bias between 
methods. The method has found its way among clinical chemists, but it 
has been criticized in 2002 that a high proportion of clinical chemists 
misinterpreted or misused the methods of differences [5]. 
The main points of criticism were: 
a) the x-axis only contained one of both methods, not the average of 
both methods;
b) the 95% limits of agreement (LOA) were not compared to a predefined 
clinically acceptable difference between the two methods and
c) the 95% LOAs were not calculated with the appropriate statistical 
methodology, especially when proportional bias is present. 
Although the first point of criticism was addressed in 1995, when 
Bland and Altman published yet another article in the Lancet [6], 
entitled “Comparing methods of measurement: why plotting difference 
against standard methods is misleading”, it seems that the Nephrology 
community is falling into the same traps as clinical chemists if they use 
the method of differences to compare estimating glomerular filtration rate 
(eGFR) equations with the direct measurement of GFR (mGFR). In their 
1995 article, Bland and Altman argued that plotting the differences against 
either of both methods, even in case one of the methods was the standard 
method, are not the appropriate way to analyse method comparison data. 
They actually wrote: “It would be a mistake to plot the difference against 
either value separately because the difference will be related to each, a 
well-known statistical artefact.” 
Bias and other method performance measures have been calculated 
numerously in the last ten years when comparing eGFR-equations with 
the direct measurement of GFR (mGFR), but also when comparing 
eGFR-equations with each other. In most of the published articles on that 
subject, Bland-Altman plots are used, but mainly only constant (or fixed) 
bias is reported. The analysis of proportional bias is circumvented by 
defining eGFR or mGFR-strata and calculating the method performance 
characteristics in these strata. However, defining strata means that the 
X-variable becomes involved in the analysis, and then the above referenced 
statistical artefact comes into play. We here demonstrate how method 
comparison should be performed, using eGFR and mGFR data, and draw 
attention to the possible pitfalls of this analysis and more specifically to 
the above mentioned three points of criticism.
Methods
In a first section, we present simulated data and statistical analyses 
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on these data to demonstrate the statistical artefact referenced in the 
introduction.
In a second section, we use a real life example obtained from the article 
of Gagneux-Brunon et al. [7] on n = 203 HIV patients for whom the gold 
standard inulin method has been used to obtain direct measurements 
for the glomerular filtration rate (mGFR), but also estimated GFR was 
obtained from serum creatinine, gender and age for different equations 
(MDRD, CKD-EPI). We analysed the data according to the method of 
differences described by Bland and Altman [1-4] and John Ludbrook [8-
10].
We here describe the procedure that should be used:
1. Check for the presence of proportional bias.  There are two 
ways to tackle that problem:
a) Calculate the mean of the ratio eGFR/mGFR and the 95% 
Confidence Interval (CI) of that mean. When the value ‘1’ is included 
in the 95% CI, there is no evidence for proportional bias; if not, there 
is evidence for the presence of proportional bias.
b) Construct a XY-scatterplot of differences (mGFR-eGFR) on 
averages (mGFR+eGFR)/2. If the slope of the regression is shown to 
statistically differ from zero, there is proportional bias; if not, there is 
no proportional bias.
2. If there is no proportional bias, and if the scatter of differences is 
uniform (homoscedasticity), calculate the mean of differences (= 
constant or fixed bias) and the standard deviation (SD) of these 
differences, from which classical 95% LOAs can be constructed: 
bias ± 1.96 SD. These 95% LOAs are 95% confidence limits for the 
population of differences. A slightly better definition of the 95% LOAs 
is given by:
bias ± (t0.05, n-1) × SD. 
The value t0.05, n-1 tends to 1.96 when n → ∞. 
3. If there is proportional bias yet homoscedasticity, construct hyperbolic 
95% LOAs around the line of best fit. These 95% LOAs are called 
prediction intervals. The formulas for prediction intervals around a 
straight line fit can easily be obtained from statistical handbooks.
4. If there is proportional bias and the scatter of differences increases 
progressively as the average values increase (heteroscedasticity), 
a phenomenon frequently observed when comparing eGFR to 
mGFR, an appropriate transformation (e.g. log-transformation) of 
the raw values from both methods and re-plotting the differences 
against averages may eliminate the proportional bias and/or 
heteroscedasticity. If this is the case, classical 95% LOAs may be 
constructed; otherwise V-shaped 95% LOAs around the line of best fit 
of differences on averages should be constructed.
5. Compare the obtained 95% LOAs to predefined clinically acceptable 
limits. If the 95% LOAs fall within the predefined criteria, you may 
accept the new method to replace the (g)old method, otherwise, reject 
the new method.
The method to calculate V-shaped 95% LOAs in case of proportional 
bias or heteroscedasticity is described by Ludbrook [10] who by chance 
came across a website in which Bland and Altman [11] described how to 
calculate this. The steps are as follows:
1. Construct the least squares regression of differences on averages: 
difference = A + B × average
2. Extract the residuals as the differences between observed and 
predicted values
3. Convert the residuals into absolute values (by removing the negative 
signs)
4. Construct the least squares regression of absolute residuals on 
averages:
absolute residual = a + b × average
5. Adjust the coefficients for regression of absolute residuals on averages 
by multiplying them by   = 1.2533, resulting in
SD = 1.2533 a + (1.2533 b) × average
6. The V-shape LOAs are then obtained by calculating predicted 
difference ± 1.96 × SD
or
A + B × average ± 1.96 × (1.2533 a + (1.2533 b) × average)
Results
Simulated illustration of the statistical artefact
The statistical artefact mentioned by Bland and Altman can easily 
been illustrated by randomly generating eGFR and mGFR values. We 
therefore used the RANDBETWEEN (1,125) worksheet function in MS 
Excel to generate 30 random numbers between 1 and 125 for eGFR, 
and independently for mGFR. These random values are assigned to 30 
hypothetical patients in a paired way, so that each patient has an eGFR-
value and a mGFR-value which are random and completely independent 
from each other. For each hypothetical patient, the difference mGFR-eGFR 
is then plotted against the average [mGFR+eGFR]/2 (Figure 1a), but also 
against eGFR and mGFR separately. As eGFR and mGFR were randomly 
generated, independent of each other, no relation exists between eGFR 
and mGFR, which is also apparent when plotting differences on averages. 
However, when plotting the difference mGFR-eGFR against eGFR (Figure 
1b), the obtained pattern showed a striking linear relationship (R2 = 
0.7328, p < 0.0001) with a negative slope. When plotting the difference 
mGFR-eGFR against mGFR, we observe an increasing linear trend line 
(positive slope, R2 = 0.7355, p < 0.0001) (Figure 1c). This is entirely an 
artefact of data analysis. Graphing a difference between methods against 
either method separately is quite misleading. Attributing a significant 
correlation on such a graph to method association is termed regression 
fallacy. Such a plot should not be analysed by linear regression because 
these data violate one of the assumptions of linear regression, that the X 
and Y variables were determined independently [12].
In fact, there is nothing wrong with plotting differences against 
one of the variables separately, unless we start analysing the data and 
we involve the X-variable in the analysis. In case we are performing 
regression analysis, we are violating one of the basic assumptions of linear 
regression, that the X and Y variables were determined independently. But 
also performing subgroup analysis, by stratifying on mGFR or eGFR, is 
misleading, because the choice of the subgroup is not independent from 
the variable under study. Moreover, subgroup analysis is performed as a 
replacement for analysing proportional bias. In case there is absence of 
proportional bias, subgroup analysis should present approximately equal 
fixed biases in each subgroup. In our example, where the values of both 
methods are obtained by a random number generator, the bias equals 
zero (Figure 1a). However, subgroup analysis, based on eGFR will give 
positive bias when eGFR< 60, and negative bias when eGFR> 90, while 
the opposite is true when mGFR is used to define subgroups (negative bias 
when mGFR< 60 and positive bias when mGFR>90).
In the opposite situation when proportional bias is present in the 
differences on average plot, then this bias may be hidden when differences 
or plotted against one of both methods, due to the same statistical artefact.
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Plotting differences against average or against either of both 
methods? Real life example
We start from an example using a dataset of n = 203 HIV patients [7] for 
whom GFR was measured directly using the inulin methodology (mGFR) and 
estimated from different so-called estimating equations (eGFR). We compare 
the eGFR-MDRD equation with the direct GFR measurement (mGFR), using 
the Bland-Altman methodology described in the methods section.
Step 1. Calculating the mean of the ratio eGFR/mGFR, we find 1.042 
with 95% CI [0.996 – 1.088] from which we conclude that there is no 
proportional bias, as ‘1’ is included in the 95% CI. Plotting the ratio 
eGFR/mGFR against the average (Figure 2a) also reveals the presence 
of 2 outliers in the low GFR region. When omitting these outlying 
observations, the mean ratio becomes 1.027 with 95% CI [0.986 – 1.069] 
which does not change our conclusion that there is no proportional bias. 
Plotting the differences against the average and performing regression 
analysis gives R2 = 0.0245 with p = 0.026, indicating a small but 
statistically significant increasing trend in the data (Figure 2b). Omitting 
the two outliers from this analysis reduces the R2 from 0.0245 to 0.0157 
and returns the borderline significance into non-significance (p = 0.075). 
As both methods to evaluate the presence of proportional bias are not 
completely equivalent, and because the observed trend is extremely 
small, we conclude that the proportional bias is relatively small and may 
therefore be ignored. The least squares methodology is heavily influenced 
by the leverage effect due to squaring of the deviations. Calculating the 
mean of eGFR/mGFR balances deviations from ‘1’ under and above this 
value, just like calculating the mean of mGFR-eGFR balances positive and 
negative deviations. In this sense, the calculation is very analogous and is 
the preferred way to indicate the presence or absence of proportional bias. 
It is really like comparing the data with the identity line when plotting 
eGFR against mGFR (but without performing regression analysis): the 
identity line goes through zero (and this is equivalent to zero constant 
bias) and has a slope of ‘1’ (equivalent to a ratio eGFR/mGFR equal to ‘1’, 
an indication of the absence of proportional bias).
When plotting the same differences mGFR-eGFR against either of 
both methods (eGFR or mGFR) we observe the effect explained by Bland 
and Altman and described in the first part of the results section. When 
mGFR-eGFR is plotted against eGFR, there is an observed negative trend 
(Figure 2c), but when plotted against mGFR, there is an observed positive 
trend (Figure 2d). In both cases, the trends are much more pronounced 
(and statistically significant) than when plotting the differences against 
the average.
Analysing the proportional bias is required to calculate 95% LOAs, but 
it involves regressing mGFR-eGFR against the X-variable. In that case, the 
plots of differences against one measurement can be seriously misleading. 
In the example shown, we may conclude that there is a significant negative 
(or positive) proportional bias, while in fact, there is none. 
Step 2. The calculation of the 95% LOAs depends on the presence 
or absence of proportional bias. Ultimately, the 95% LOAs should be 
compared to clinically acceptable limits. The final decision to accept the 
new method, to replace the (g)old method, is not a statistical one but a 
medical or clinical one. The correct calculation of 95% LOAs is therefore of 
great importance. This calculation involves the X-variable in the analysis 
in case of the presence of proportional bias. The way to calculate 95% 
LOAs in the presence or absence of proportional bias has been described 
in the methods section.
If we accept that there is no proportional bias (as is indicated by the 
equality of eGFR/mGFR with ‘1’), then 95% LOAs for the difference on 
average could be calculated using bias ± 1.96 × SD = [-48; 50 ml/min/1.73 
m2] which are fixed over the complete range of average values. 
Steps 3-4. If we assume now, for the sake of this example, that there 
is proportional bias, as suggested by the small but statistically significant 
R2 = 0.0245, then Ludbrook [10] describes a methodology to calculate 
V-shaped limits for the regression of differences on averages (see methods 
section) [Figure 3]. The results for our example are shown in Figure 3. 
Around 50 ml/min/1.73 m2 the MDRD method shows an imprecision 
resulting in a possible range of differences between mGFR and eGFR 
varying between -35 to 18 ml/min/1.73 m2. This prediction range increases 
to -48 to +50 ml/min/1.73 m2 at the 100 ml/min/1.73 m2 level. 
Yet another approach would be to plot the relative differences against 
the averages. The reason for doing this is that relative differences are 
probably easier to interpret clinically, in terms of clinically acceptable 
limits as a % relative difference: e.g. a clinically acceptable limit could 
be defined as a maximum of 15% deviation. These limits could then be 
plotted on the Bland-Altman plot, together with the 95% LOAs and make 
a direct comparison possible.
In figure 4 the effect of the two outliers, previously determined, is 
clearly visible. Removing these outliers has a serious effect on the form 
of the V-shape. Assuming absence of proportional bias in this relative 
difference plot would result in fixed 95% LOAs of [-50% to +52%], not 
much different from the slightly increasing LOAs in figure 4 (right side). 
Step 5. Visual inspection of Figure 4 shows that the clinically acceptable 
limit of ±15% are much smaller than the actually obtained 95% LOAs, 
meaning that the MDRD method is not capable of accurately predicting 
the mGFR. The conclusion of this method comparison study should 
therefore be that the MDRD method could not replace the (g)old mGFR 
method.
Subgroup analysis: how to define GFR strata?
Scientists are clever and creative. This can also be seen when going 
through the most recent literature dealing with the evaluation of new 
equations for estimating GFR. To circumvent the problem of the presence 
of proportional bias and the more complex calculation of V-shaped LOAs, 
it has been recommended [13] to calculate bias and other performance 
measures (e.g. accuracy (P20, P30)) in so-called GFR-strata. These GFR-
strata are typically (but not exclusively) defined as
•	 GFR <60 ml/min/1.73 m2
•	 60 ≤ GFR ≤ 90 ml/min/1.73 m2
•	 GFR >90 ml/min/1.73 m2
Accuracy defined as P30 is the % within 30% of the measured GFR 
value, or in other words, the percentage of patients with |mGFR-eGFR|/
mGFR<0.30.
Subgroup analysis for bias
Defining GFR-strata also involves the X-variable in the analysis, as 
subgroup analysis may be seen as a replacement for analysing proportional 
bias. When proportional bias is absent, there is no need for calculating 
(constant) bias in subgroups, as these are all expected to be very equivalent 
to the overall constant bias. This is demonstrated in Figure 5a and in Table 
1 for subgroups defined based on (mGFR+eGFR)/2.
Figures 5b and 5c demonstrate the effect on bias calculation in 
subgroups based on eGFR or mGFR to define GFR-strata. When choosing 
eGFR to define GFR-strata, eGFR becomes involved in the data-analysis. 
As the known statistical artefact predicts a negative proportional bias 
(negative trend for the difference against eGFR), the bias will be higher 
in the low GFR-stratum than in the high GFR-stratum, while this will be 
reversed when mGFR was used to define GFR-strata. The calculated biases 
are shown as horizontal lines in the figures for each stratum and are given 
in Table 1.
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The calculated biases in subgroups defined by either eGFR or mGFR 
are misleading and completely a consequence of the described statistical 
artefact.
Subgroup analysis for P30
When plotting [mGFR-eGFR]/mGFR against the average of both 
methods (Figure 6a), or against eGFR (Figure 6b) or mGFR (Figure 6c), 
the limits corresponding to ± 30% define the area in which the patients 
within 30% of the mGFR are falling. This analysis is close to the analysis 
of relative differences, but not exactly the same, as relative differences in 
Figure 4 were calculated as the differences divided by the average of both 
methods.
When GFR-strata are defined based on the average, eGFR or mGFR, 
the results are very different. Strata defined by eGFR or mGFR are very 
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misleading as they suggest the presence of proportional bias, as can be 
observed by inspection of Figures 6b and 6c.The P30 values are presented 
in Table 2.
An alternative to using P30 would be to make use of the relative 
differences as explained in Figure 4 and compare the obtained 95% LOAs 
against clinically acceptable limits.
Discussion
The goal of method comparison studies is to determine whether the new 
method (eGFR) may replace the (g)old method (mGFR). In other words, 
to evaluate whether the two methods of measurement agree sufficiently 
closely. Statistical methodology may help to present and summarize the 
available data but ultimately the decision whether to accept or reject the 
new method is a clinical one. Interpretation of the Bland-Altman plots 
should be done by comparison of the observed limits of agreement to 
predefined clinically acceptable limits. Bias and imprecision may be 
unacceptably high, which may affect the clinical decision for an individual 
patient, and therefore, the new method may be rejected. 
Most importantly, the statistical methodology to compare two methods 
should be used appropriately. It seems that researchers comparing eGFR-
equations to mGFR fall into the same traps as clinical chemists a decade 
ago, if they use the method of differences [5,10]. Bland and Altman’s 
original goal was to detect bias. Bias, however, can take one (or both) 
of two forms: fixed or constant bias and proportional bias. Fixed bias 
means that one method is consistently higher (or lower) than the other 
method, across the whole range of measurement. This is indicated by 
a departure of the mean difference from zero. Unfortunately, the mean 
of differences can also be zero due to the presence of proportional bias, 
when positive and negative differences are cancelling out each other. 
Proportional bias is present when the difference in values resulting from 
the two methods are decreasing or increasing in proportion to the average 
values. Heteroscedasticity (the scatter of differences is increasing with 
increasing average) is yet another problem that should be tackled during 
method comparison studies in an appropriate way. The statistical analysis 
should result in the correct calculation of 95% Limits of Agreement, 
which should then be compared to clinically acceptable limits. This 
is the ultimate goal of method comparison. Once it is decided that the 
new method may replace the old method, there is no further need for 
method comparison studies. This is contrary to what is happening in 
eGFR method comparison studies, where multiple method comparison 
studies are performed with continuous new cohorts of patients. In 2012 
there appeared a systematic review [13] on method comparison studies 
to evaluate the performance of (mainly) the MDRD Study equation and 
the CKD-EPI equation to estimate GFR. This review article identified 23 
method comparison studies based on serum creatinine assays traceable 
to SRM (serum reference material). However, their search yielded 3250 
abstracts on this subject. The conclusion of this review article was that 
neither the CKD-EPI nor the MDRD Study equation is optimal for all 
populations and GFR ranges. This is a euphemism for saying that the 
CKD-EPI and MDRD Study equation do not fulfil the clinically acceptable 
limits, because bias and (mainly) imprecision are simply unacceptable. 
This same review made an (appreciated) attempt to suggest criteria 
for developing and validating GFR estimating equations. The authors 
proposed that measures of equation performance should include bias, 
precision and accuracy and they encourage researchers to report P30 and 
P20. A relative reduction in bias of 50% or RMSE (root mean square error) 
of 20% in relevant age and GFR-strata was presented as the goal to achieve. 
The same authors presented median difference and 1-P30 in eGFR-strata 
[14]. However, this is not the way method comparison statistics should 
be applied. Rule [15] criticized the fact that in some studies mGFR-strata 
were used. He referred to Motulsky [11] to argue why eGFR-strata should 
be used instead of mGFR-strata. He argued that mGFR-strata could not 
be used because eGFR-mGFR will have a negative trend with higher levels 
of mGFR, a fact that we here identified as the regression fallacy. It should 
be noted that exactly the same arguments can be used to show that eGFR-
strata are not appropriate. Both choices are misleading as explained in 
the results section of this study. Arguing that, from a clinical perspective, 
it is not helpful to assess equation performance across levels of mGFR 
because if you know mGFR you would not need to estimate it, and use this 
argument to state that equation performance should be assessed across 
levels of eGFR, is difficult to understand. The goal of a method comparison 
study is either to accept or to reject the new method for replacing the old 
method. When the new method is acceptable, there is no further need 
for measuring mGFR, because the estimated GFR is reliable and close 
enough to the mGFR. This is exactly what happened when enzymatic 
serum creatinine replaced Jaffe type assays. The enzymatic assay results 
were compared to the gold standard (IDMS) and it was concluded that the 
new method (enzymatic assay) was close enough to the gold method. The 
fact that we may not conclude this for eGFR methods is the real problem. 
In the same article, the author explains how “absolute bias” (the mean of 
absolute value of differences) should be interpreted. Introducing statistical 
concepts like the absolute bias have only one purpose: to circumvent the 
problem of proportional bias, as absolute bias is used because positive 
and negative differences may cancel out each other. There is no need to 
introduce ‘new’ definitions of bias when proportional bias is analysed 
appropriately.
The group of Levey [13,14,16-22] have dictated that it is preferable to 
evaluate equation performance based on eGFR rather than on mGFR to 
minimize the effect of regression to the mean, and others claim that mGFR 
should be used because mGFR is the (g)old standard method. Both are 
misleading. Differences between methods should be plotted on averages, 
not on either of both methods. Bias and accuracy (P10,P30) in eGFR and 
mGFR-subgroups should not be calculated, as they are misleading. The 
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Figure 3: V-shape limits for the regression of differences on averages 
(Ludbrook7)
Stratum [mGFR+eGFR]/2 eGFR mGFR
<60 ml/min/1.73 m2 -0.7 +8.2 -26.7
60 ≤ GFR ≤ 90 ml/min/1.73 m2 -2.9 +9.9 -7.1
>90 ml/min/1.73 m2 +3.9 -5.7 +9.9
Table 1: Bias according to different GFR strata
Stratum [mGFR+eGFR]/2 eGFR mGFR
<60 ml/min/1.73 m2 63 50 22
60 ≤ GFR ≤ 90 ml/min/1.73 m2 71 83 75
>90 ml/min/1.73 m2 78 72 83
Table 2: P30 (%) according to different GFR strata
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Figure 4: V-shaped 95% LOAs with and without 2 outliers. Clinically acceptable limits of 15% are drawn to make a direct comparison possible with the 
95% LOAs.
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Figure 5: Effect on bias in subgroups defined by (mGFR+eGFR)/2, eGFR and mGFR.
Figure 6: Effect on P30 in subgroups defined by (mGFR+eGFR)/2, eGFR and mGFR.
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subgroups should be defined as (eGFR+mGFR)/2-strata. In this sense, 
we should preferably refer to bias and accuracy in ‘GFR-subgroups’ or at 
specific ‘GFR-levels’. These levels should be defined based on the average 
of both methods.
The problem with method comparison studies to evaluate the 
performance of eGFR equations is that we cannot decide to ‘reject’ the 
eGFR-equation because the alternative is the cumbersome and complex 
direct measurement of GFR. Therefore, we continue using eGFR-equations 
that are far from optimal and that we continuously evaluate. This has led 
to a mass production of articles on that subject and it will probably lead to 
a mass production of articles on that subject in the coming years.
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